Bioabsorbable Polymer Carrier with Hydroxyapatite Coating for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional angiogenesis therapies face challenges in generating sufficient new blood vessels due to low cell retention at the local site, high invasiveness, and side effects associated with animal-derived carriers.
Innovation Solution
A medical composition featuring a bioabsorbable polymer carrier coated with hydroxyapatite, which supports cells and includes angiogenesis cytokines, allowing for effective angiogenesis with reduced invasiveness and toxicity, and easy administration using an injector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cell transplantation methods are used to induce angiogenesis, then new blood vessels can be generated, but cell retention at the local site is low and the therapy is highly invasive
Solution Approach 1:
The patent introduces a carrier as an intermediary substance that mediates between the transplanted cells and the ischemic tissue. The carrier protects cells from circulating away, provides a local microenvironment for cell survival and differentiation, and facilitates controlled release of growth factors, thereby improving cell retention and reducing invasiveness while maintaining angiogenesis effectiveness
Solution Approach 2:
The patent modifies the physical and chemical parameters of the carrier (such as porosity, surface area, degradation rate, and growth factor concentration) to optimize cell attachment, survival, and function. By adjusting these parameters, the system achieves high cell retention and effective angiogenesis with reduced invasiveness
2Reliability
If animal-derived carriers are used to deliver cells and growth factors, then angiogenesis can be enhanced, but side effects and toxicity increase
Solution Approach 1:
The patent changes the material composition parameter of the carrier from animal-derived materials to synthetic biocompatible polymers. This substitution eliminates immunogenicity and toxicity associated with animal products while maintaining the carrier's functional properties such as biodegradability, porosity, and ability to support cell attachment and growth factor delivery
Solution Approach 2:
The patent employs composite material structures combining synthetic polymer matrices with bioactive components (such as peptides or minerals) that mimic the functional properties of natural extracellular matrix. This composite approach provides effective angiogenesis support without the harmful effects of animal-derived materials
3Reliability
If a large number of cells are transplanted to achieve effective angiogenesis, then new blood vessel generation improves, but patient burden and invasiveness increase
Solution Approach 1:
The patent performs preliminary actions by pre-coating the carrier with growth factors and pre-attaching cells to the carrier before transplantation. This preliminary preparation ensures that cells are immediately protected and supported upon implantation, maximizing their survival and angiogenic activity with a smaller number of transplanted cells, thereby reducing patient burden
Solution Approach 2:
The carrier is designed to provide self-service functions including sustained release of growth factors, maintenance of optimal microenvironment conditions, and protection of transplanted cells. This self-service capability enhances angiogenesis effectiveness with minimal cell numbers, reducing the need for large-scale cell transplantation and associated patient burden
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively generates new blood vessels with a small number of cells, reduces patient burden, and minimizes side effects by degrading after angiogenesis, ensuring biological safety and ease of administration.
Implementation Method 1
a carrier in a particle form, the carrier having (i) a support made from a bioabsorbable polymer and (ii) a surface layer made from hydroxyapatite and provided on the support; and cells provided on a surface of the carrier
Implementation Method 2
support made from a bioabsorbable polymer
Data Source
AI summary
In order to provide (i) a medical composition that has a strong angiogenic effect, has low invasiveness to a body of a patient, and is easy to administer to a living subject and (ii) a medical kit using a medical composition, the medical composition includes: a carrier in a particle form, the carrier having (a) a support made from a bioabsorbable polymer and (b) a surface layer made from hydroxyapatite and provided on the support; and cells provided on a surface of the carrier.